{"id":"W3081590106","doi":"10.1158/1538-7445.am2020-ct162","title":"Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Cohort; Internal medicine; Neutropenia; Refractory (planetary science); Clinical trial; Oncology; Cancer; Toxicity; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001748283,0.002118535,0.001619068,0.0004112925,0.0004087381,0.001243907,0.001159431,0.001021766,0.00628725],"category_scores_gemma":[0.001014331,0.000595698,0.001360478,0.0004206752,0.0007788742,0.0007365605,0.0004799725,0.004036831,0.001901877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000991761,"about_ca_system_score_gemma":0.001691029,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008302725,"about_ca_topic_score_gemma":0.001809435,"domain_scores_codex":[0.9995617,0.0002288499,0.00002565706,0.00007410202,0.00005511066,0.00005452879],"domain_scores_gemma":[0.9992527,0.00008778901,0.0001943758,0.00008353766,0.0000559266,0.0003255949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7620633,0.04950197,0.01417461,0.001286773,0.001980403,0.0004798087,0.0002290107,0.002265717,0.08754824,0.0002855515,0.009541865,0.07064278],"study_design_scores_gemma":[0.6363786,0.3206312,0.02253139,0.00008148142,0.001100707,0.0009782607,0.00004916736,0.001224024,0.01044233,0.0001881189,0.006343849,0.00005084016],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847267,0.002938041,0.0006373689,0.000660125,0.0001192911,0.002905785,0.004453477,0.0001686716,0.003390629],"genre_scores_gemma":[0.9673129,0.002500013,0.002655929,0.001254145,0.0003263946,0.004082472,0.01389253,0.00009711283,0.007878561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00628725,"threshold_uncertainty_score":0.02103293,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04802705472500542,"score_gpt":0.3721562432470194,"score_spread":0.324129188522014,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}